X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1241) 1241
humans (960) 960
male (609) 609
animals (518) 518
hypolipidemic agents - therapeutic use (513) 513
pharmacology & pharmacy (474) 474
hypolipidemic agents - pharmacology (434) 434
hypolipidemic agents - pharmacokinetics (392) 392
female (327) 327
hypolipidemic agents - administration & dosage (273) 273
rats (257) 257
adult (251) 251
hypolipidemic agents - adverse effects (235) 235
middle aged (213) 213
cholesterol (199) 199
hyperlipidemias - drug therapy (186) 186
drug interactions (174) 174
lipids (160) 160
fenofibrate (158) 158
statins (150) 150
risk factors (144) 144
pharmacokinetics (142) 142
dyslipidemias - drug therapy (138) 138
triglycerides - blood (137) 137
aged (133) 133
hypolipidemic agents - chemistry (133) 133
drug therapy, combination (129) 129
treatment outcome (127) 127
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (125) 125
mice (125) 125
coronary-heart-disease (121) 121
chemistry, medicinal (120) 120
lipids - blood (118) 118
metabolism (115) 115
dose-response relationship, drug (113) 113
cardiac & cardiovascular systems (112) 112
administration, oral (108) 108
biological availability (108) 108
abridged index medicus (107) 107
atherosclerosis (106) 106
fenofibrate - pharmacokinetics (105) 105
hypolipidemic agents - blood (104) 104
cholesterol - blood (102) 102
dyslipidemia (100) 100
hyperlipidemia (99) 99
simvastatin (98) 98
cardiovascular disease (97) 97
rats, sprague-dawley (97) 97
cholesterol, ldl - blood (95) 95
drug therapy (95) 95
medicine & public health (90) 90
research (90) 90
triglycerides (89) 89
biochemistry & molecular biology (87) 87
gemfibrozil (87) 87
analysis (86) 86
cardiovascular diseases - prevention & control (86) 86
fenofibrate - therapeutic use (84) 84
cross-over studies (82) 82
fenofibrate - administration & dosage (82) 82
pharmacology/toxicology (82) 82
hypolipidemic agents - metabolism (79) 79
area under curve (78) 78
health aspects (78) 78
liver - metabolism (75) 75
drugs (74) 74
therapy (73) 73
endocrinology & metabolism (70) 70
safety (70) 70
clinical trials as topic (69) 69
lipoproteins (69) 69
liver - drug effects (69) 69
solubility (69) 69
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (68) 68
hypercholesterolemia (68) 68
density-lipoprotein cholesterol (67) 67
double-blind method (67) 67
fibric acids (67) 67
rats, wistar (67) 67
time factors (67) 67
cardiovascular-disease (65) 65
gemfibrozil - pharmacology (65) 65
cardiology (63) 63
care and treatment (63) 63
cholesterol, hdl - blood (63) 63
bioavailability (62) 62
liver (62) 62
medicine, general & internal (62) 62
half-life (60) 60
chromatography, high pressure liquid (59) 59
diabetes (58) 58
kinetics (58) 58
low density lipoproteins (57) 57
niacin - therapeutic use (57) 57
pharmacology (57) 57
fenofibrate - adverse effects (56) 56
fenofibrate - pharmacology (56) 56
physiological aspects (56) 56
efficacy (55) 55
risk (55) 55
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1244) 1244
German (19) 19
French (14) 14
Russian (12) 12
Spanish (5) 5
Chinese (3) 3
Czech (3) 3
Japanese (3) 3
Polish (3) 3
Italian (2) 2
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2009, Volume 54, Issue 17, pp. 1609 - 1616
Objectives We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects. Background Statin-induced side effects can... 
Cardiovascular | Internal Medicine | clinical trial | hydroxymethylglutaryl-CoA reductase inhibitors | adverse events | single nucleotide polymorphisms | myopathy | pharmacogenetics | TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | ACID | SAFETY | SLCO1B1 POLYMORPHISM | INDUCED MYOPATHY | ATORVASTATIN | PHARMACOKINETICS | DISEASE | PRAVASTATIN | LACTONE | Haplotypes | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Male | Heptanoic Acids - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Pravastatin - adverse effects | Pyrroles - adverse effects | Female | Muscular Diseases - chemically induced | Hypolipidemic Agents - adverse effects | Creatine Kinase - blood | Simvastatin - pharmacokinetics | Muscular Diseases - blood | Atorvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Aged | Polymorphism, Single Nucleotide | Hypolipidemic Agents - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Pravastatin - pharmacokinetics | Enzymes | Hypotheses | Acids | Mortality | Cardiovascular disease | Muscle pain | Drug therapy | Statins | Cholesterol | Index Medicus | Abridged Index Medicus | muscular diseases | hydroxymethylglutaryl-CoA Reductase Inhibitors
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 4/2013, Volume 30, Issue 4, pp. 1188 - 1199
Quantitative prediction of complex drug-drug interactions (DDIs) is challenging. Repaglinide is mainly metabolized by cytochrome-P-450 (CYP)2C8 and CYP3A4, and... 
Biochemistry, general | Biomedical Engineering | repaglinide | CYP2C8 | Biomedicine | physiologically-based pharmacokinetic model | Pharmacy | Medical Law | Pharmacology/Toxicology | gemfibrozil | drug-drug interaction | OATP1B1 | GLUCURONIDE INHIBIT | IN-VITRO CLEARANCE | METABOLIC PATHWAYS | HUMAN LIVER-MICROSOMES | HEPATIC-UPTAKE | CHEMISTRY, MULTIDISCIPLINARY | INHIBITION MECHANISMS | SANDWICH CULTURE | PLASMA-CONCENTRATIONS | TISSUE DISTRIBUTION | PHARMACOLOGY & PHARMACY | Cytochrome P-450 CYP2C8 | Humans | Hepatocytes - metabolism | Carbamates - pharmacokinetics | Organic Anion Transporters - metabolism | Drug Interactions | Piperidines - pharmacology | Piperidines - pharmacokinetics | Hypolipidemic Agents - chemistry | Hepatocytes - drug effects | Carbamates - pharmacology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Hypoglycemic Agents - pharmacokinetics | Organic Anion Transporters - antagonists & inhibitors | Biological Transport, Active - drug effects | Gemfibrozil - pharmacokinetics | Gemfibrozil - pharmacology | Hypolipidemic Agents - pharmacology | Aryl Hydrocarbon Hydroxylases - metabolism | Hypoglycemic Agents - pharmacology | Models, Biological | Gemfibrozil - analogs & derivatives | Hypolipidemic Agents - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Side effects | Pharmacology | Liver | Pharmaceuticals | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2017, Volume 19, Issue 12, pp. 1762 - 1772
Aims: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analogue, in... 
fibroblast growth factor 21 | blood pressure | 1 | heart rate | type 2 diabetes | bone biomarkers | IGF | IGF-1 | FATTY LIVER-DISEASE | ENERGY-EXPENDITURE | PF-05231023 | PROFILE | PHARMACOKINETICS | ENDOCRINOLOGY & METABOLISM | MICE | FGF21 | Hypertriglyceridemia - drug therapy | Fibroblast Growth Factors - adverse effects | Follow-Up Studies | Obesity - drug therapy | Species Specificity | Humans | Middle Aged | Half-Life | Anti-Obesity Agents - adverse effects | Male | Obesity - blood | Anti-Obesity Agents - therapeutic use | Bone Remodeling - drug effects | Delayed-Action Preparations - administration & dosage | Dose-Response Relationship, Drug | Anti-Obesity Agents - pharmacokinetics | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Fibroblast Growth Factors - administration & dosage | Hypertension - chemically induced | Delayed-Action Preparations - pharmacokinetics | Female | Drug Resistance | Fibroblast Growth Factors - therapeutic use | Body Mass Index | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Hypolipidemic Agents - adverse effects | Anti-Obesity Agents - administration & dosage | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Drug Administration Schedule | Obesity - complications | Biomarkers - blood | Hypertension - physiopathology | Hypertriglyceridemia - blood | Animals | Fibroblast Growth Factors - pharmacokinetics | Delayed-Action Preparations - adverse effects | Hypertriglyceridemia - complications | Hypolipidemic Agents - administration & dosage | Delayed-Action Preparations - therapeutic use | Hypolipidemic Agents - therapeutic use | Infusions, Intravenous | Hypolipidemic Agents - pharmacokinetics | Type 2 diabetes | Obesity | Heart beat | Blood cholesterol | Collagen | Analysis | Body weight | Primates | Fibroblast growth factors | Blood pressure | Fibroblast growth factor | Pharmacodynamics | Diabetes mellitus | Homeostasis | Lipids | Triglycerides | Body weight loss | Bone turnover | Monkeys & apes | Cholesterol | Adiponectin | Heart rate | Rodents | Fibroblasts | Atorvastatin | Lead | Safety | Pharmacokinetics | Growth factors | Diabetes mellitus (non-insulin dependent) | Lipoproteins (high density) | Index Medicus
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 02/2008, Volume 51, Issue 3, pp. 380 - 383
Journal Article
by Shi, NQ and Wang, SR and Zhang, Y and Huo, JS and Wang, LN and Cai, JH and Li, ZQ and Xiang, B and Qi, XR
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ISSN 0928-0987, 03/2019, Volume 130, pp. 78 - 90
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 07/2014, Volume 54, Issue 7, pp. 800 - 808
ABSTRACTPradigastat, a novel diacylglycerol acyltransferase-1 inhibitor, was evaluated for both pharmacokinetic (PK) and pharmacodynamic (PD) drug–drug... 
pharmacokinetics | interaction | digoxin | pharmacodynamics | warfarin | PHARMACOLOGY & PHARMACY | Acetates - adverse effects | Acetates - blood | Digoxin - adverse effects | Enzyme Inhibitors - blood | Humans | Middle Aged | Prothrombin Time | Aminopyridines - pharmacokinetics | Aminopyridines - adverse effects | Half-Life | Warfarin - adverse effects | Male | Metabolic Clearance Rate | Diacylglycerol O-Acyltransferase - antagonists & inhibitors | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Young Adult | Hypolipidemic Agents - blood | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Cardiotonic Agents - adverse effects | Adult | Female | Digoxin - blood | Enzyme Inhibitors - adverse effects | Aminopyridines - administration & dosage | Hypolipidemic Agents - adverse effects | Reproducibility of Results | Cardiotonic Agents - pharmacokinetics | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | International Normalized Ratio | Acetates - administration & dosage | Aminopyridines - blood | Cardiotonic Agents - blood | Warfarin - blood | Adolescent | Hypolipidemic Agents - administration & dosage | Hypolipidemic Agents - pharmacokinetics | Acetates - pharmacokinetics | Cohort Studies | Warfarin | Dosage and administration | Digoxin | Pharmacokinetics | Analysis | Drug interactions | Prescription drugs | Index Medicus
Journal Article
Pharmaceutical Biology, ISSN 1388-0209, 01/2017, Volume 55, Issue 1, pp. 510 - 515
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 06/2015, Volume 43, Issue 6, pp. 803 - 811
PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, was generated by covalently conjugating two engineered [des-His1, Ala129Cys]FGF21... 
PBPK MODEL | NEONATAL FC-RECEPTOR | PLASMA | LYMPHATIC TRANSPORT | THERAPEUTIC PROTEINS | IN-VIVO | PHARMACOLOGY & PHARMACY | MONOCLONAL-ANTIBODIES | BINDING | FGF21 | PREDICTION | Mutant Proteins - pharmacokinetics | Immunoglobulin G - blood | Humans | Fibroblast Growth Factors - genetics | Half-Life | Macaca fascicularis | Male | Metabolic Clearance Rate | Drugs, Investigational - analysis | Fibroblast Growth Factors - chemistry | Fibroblast Growth Factors - metabolism | Hypolipidemic Agents - blood | Hypoglycemic Agents - administration & dosage | Proteolysis | Injections, Subcutaneous | Hypolipidemic Agents - chemistry | Hypoglycemic Agents - pharmacokinetics | Immunoglobulin G - chemistry | Rats | Recombinant Proteins - chemistry | Fibroblast Growth Factors - pharmacology | Immunoglobulin G - genetics | Models, Biological | Hypolipidemic Agents - pharmacokinetics | Immunoglobulin G - metabolism | Injections, Intravenous | Drugs, Investigational - pharmacokinetics | Recombinant Proteins - pharmacokinetics | Mutant Proteins - blood | Drugs, Investigational - chemistry | Hypoglycemic Agents - blood | Antibodies, Monoclonal, Humanized - administration & dosage | Fibroblast Growth Factors - administration & dosage | Antibodies, Monoclonal, Humanized - blood | Antibodies, Monoclonal, Humanized - pharmacology | Peptide Fragments - blood | Drug Evaluation, Preclinical | Immunoglobulin kappa-Chains - blood | Hypoglycemic Agents - chemistry | Immunoglobulin kappa-Chains - metabolism | Recombinant Proteins - administration & dosage | Mutant Proteins - administration & dosage | Recombinant Proteins - blood | Immunoglobulin kappa-Chains - genetics | Animals | Fibroblast Growth Factors - blood | Mutant Proteins - chemistry | Hypolipidemic Agents - administration & dosage | Drugs, Investigational - administration & dosage | Immunoglobulin kappa-Chains - chemistry | Amino Acid Substitution | Antibodies, Monoclonal, Humanized - chemistry | Index Medicus
Journal Article
Journal Article